| Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates |
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma |
globenewswire.com |
2025-05-13 20:15:00 |
Czytaj oryginał (ang.) |
| CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT |
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Checkpoint Therapeutics, Inc. (NasdaqCM: CKPT) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Checkpoint will receive $4.10 per share and a contingent value right for up to $0.70 per share on achievement of a milestone. KSF is seeking to d. |
businesswire.com |
2025-04-29 16:19:00 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates |
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma |
globenewswire.com |
2025-03-28 10:30:00 |
Czytaj oryginał (ang.) |
| CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT |
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Checkpoint Therapeutics, Inc. (NasdaqCM: CKPT) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Checkpoint will receive $4.10 per share and a contingent value right for up to $0.70 per share on achievement of a milestone. KSF is seeking to determ. |
businesswire.com |
2025-03-14 13:17:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation into Fairness of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) Buyout Offer and Encourages Investors to Contact the Firm to Discuss Their Legal Rights and Options |
PHILADELPHIA, March 13, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating the fairness of the recently announced buyout of Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT) shareholders. |
globenewswire.com |
2025-03-13 10:01:00 |
Czytaj oryginał (ang.) |
| CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma |
NEW YORK , March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed $4.10 per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) to Sun Pharmaceutical Industries, Inc. The firm is concerned about conflicts relating to Checkpoint's controlling shareholder, Fortress Biotech, Inc. (Nasdaq: FBIO), which has secured special benefits in the deal. For a free consultation, or to learn more, contact partner W. |
prnewswire.com |
2025-03-10 20:41:00 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics shares pop on acquisition by Sun Pharma |
Checkpoint Therapeutics (NASDAQ:CKPT) shares added more than 60% after it was revealed the immunology and targeted oncology firm will be acquired by Sun Pharmaceutical Industries. Under the agreement, Sun Pharma will acquire Checkpoint for $4.10 per share in cash, representing up to $355 million in upfront payments. |
proactiveinvestors.com |
2025-03-10 15:23:53 |
Czytaj oryginał (ang.) |
| Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders |
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Checkpoint (Nasdaq: CKPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Pharma. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Checkpoint stockholders will receive an upfront cash payment of only $4.10, without interest, and a n. |
businesswire.com |
2025-03-10 03:13:00 |
Czytaj oryginał (ang.) |
| Sun Pharma to Acquire Checkpoint Therapeutics |
Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise Will leverage Sun Pharma's global presence toaccelerate patient access to UNLOXCYT™ (cosibelimab-ipdl) Upfront cash payment of $4.10 per share of common stock,representing aggregate upfront consideration of up to $355 million Stockholders will also receive a contingent value right forup to $0.70 per share on achievement of a milestone Acquisition is subject to approval by Checkpoint's stockholdersand other customary closing conditions MUMBAI, India and WALTHAM, Mass., March 9, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, "Sun Pharma")) and Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) ("Checkpoint") today announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy and targeted oncology company. |
prnewswire.com |
2025-03-10 00:06:00 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval |
Checkpoint Therapeutics, Inc. received FDA approval for Unloxcyt, the first PD-L1 drug for advanced cSCC, with strong clinical results and a market-disruptive pricing strategy. Despite mixed investor reactions, Unloxcyt's potential $1.6B peak sales and competitive pricing could make it a transformative player in the cSCC market. Risks include high competition, commercialization costs, and potential IP challenges, but Checkpoint's strategic partnerships and marketing are crucial for success. |
seekingalpha.com |
2024-12-18 15:19:16 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) |
UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma |
globenewswire.com |
2024-12-13 20:15:00 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date |
Checkpoint Therapeutics, Inc.'s cosibelimab shows promising efficacy and safety in treating cSCC, with a high tumor occupancy rate and strong clinical data. The upcoming PDUFA date on December 28th is crucial, with potential FDA approval driving significant market growth and revenue projections. Despite competitive pressures and financial risks, cosibelimab's unique mechanism and strong IP position offer substantial market opportunities in cSCC and beyond. |
seekingalpha.com |
2024-11-14 18:20:35 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates |
Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2024, and recent corporate updates. |
globenewswire.com |
2024-11-12 18:30:00 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 |
Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024 Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024 |
globenewswire.com |
2024-09-16 11:30:00 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference |
WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 10:00 a.m. ET. The Company will also attend in-person and virtual one-on-one meetings during the conference. |
globenewswire.com |
2024-09-04 12:00:00 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market Success |
Checkpoint Therapeutics' Cosibelimab, an anti-PD-L1 antibody, shows promise for treating cSCC, with potential FDA approval by December 2024, making CKPT a speculative "buy." Cosibelimab's dual mechanism of action, engaging both T cells and NK cells, offers a competitive edge over other PD-L1 inhibitors, enhancing its efficacy. Despite CKPT's low cash reserves and regulatory risks, the potential market for Cosibelimab in cSCC treatment is estimated at over $1 billion in the US. |
seekingalpha.com |
2024-08-27 20:50:40 |
Czytaj oryginał (ang.) |
| What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock |
Checkpoint Therapeutics (CKPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-08-16 17:00:33 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates |
WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2024, and recent corporate updates. |
globenewswire.com |
2024-08-12 12:30:00 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma |
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Checkpoint's resubmission of its Biologics License Application (“BLA”) for cosibelimab, its anti-programmed death ligand-1 (“PD-L1”) antibody, as a potential new treatment for adults with metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”) who are not candidates for curative surgery or curative radiation. |
globenewswire.com |
2024-07-25 11:30:00 |
Czytaj oryginał (ang.) |
| GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research |
YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoint Therapeutics ("Checkpoint") (Nasdaq: CKPT) have announced a collaboration to explore the combined therapeutic potential of cosibelimab, Checkpoint's anti-PD-L1 antibody with dual mechanism of action, with GC Cell's Immuncell-LC, an innovative autologous Cytokine Induced Killer (“CIK”) T cell therapy composed of cytotoxic T lymphocytes and natural killer T cells. |
globenewswire.com |
2024-07-15 12:00:00 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules |
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional investor for the issuance and sale of an aggregate of 5,853,659 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.05 per share of common stock (or per common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, Checkpoint will issue and sell unregistered warrants to purchase up to 5,853,659 shares of common stock. The warrants will have an exercise price of $2.05 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrant and will expire five years following the issuance date. |
globenewswire.com |
2024-07-02 12:00:00 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab |
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has completed the resubmission of its Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for cosibelimab, its anti-programmed death ligand-1 (“PD-L1”) antibody, as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”) who are not candidates for curative surgery or curative radiation. |
globenewswire.com |
2024-07-02 11:00:00 |
Czytaj oryginał (ang.) |
| Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission |
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has reached alignment with the Food and Drug Administration (“FDA”) on its biologics license application (“BLA”) resubmission strategy for cosibelimab. Accordingly, Checkpoint plans to move forward with a mid-year BLA resubmission seeking the U.S. marketing approval for cosibelimab as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”) who are not candidates for curative surgery or curative radiation. |
globenewswire.com |
2024-06-24 11:30:00 |
Czytaj oryginał (ang.) |
| CHECKPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating Checkpoint Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm |
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) on behalf of long-term stockholders following a class action complaint that was filed against Checkpoint on April 5, 2024 with a Class Period from March 10, 2021 to December 15, 2023. Our investigation concerns whether the board of directors of Checkpoint have breached their fiduciary duties to the company. |
globenewswire.com |
2024-06-06 02:00:00 |
Czytaj oryginał (ang.) |
| CKPT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm |
LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ:CKPT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 10, 2021 and December 15, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before June 4, 2024. |
accesswire.com |
2024-06-04 15:00:00 |
Czytaj oryginał (ang.) |
| CKPT DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action – CKPT |
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March 10, 2021 and December 15, 2023, both dates inclusive (the “Class Period”), of the important June 4, 2024 lead plaintiff deadline. |
globenewswire.com |
2024-06-03 23:08:00 |
Czytaj oryginał (ang.) |
| The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Checkpoint Therapeutics, Inc. (CKPT) |
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming June 4, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT) securities between March 10, 2021 and December 15, 2023, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On December 18, 2023, Checkpoint disclosed that. |
businesswire.com |
2024-06-03 20:24:00 |
Czytaj oryginał (ang.) |
| INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint |
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT) and reminds investors of the June 4, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. |
globenewswire.com |
2024-06-03 16:21:00 |
Czytaj oryginał (ang.) |
| CKPT DEADLINE UPDATE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm |
LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ:CKPT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 10, 2021 and December 15, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before June 4, 2024. |
accesswire.com |
2024-06-03 16:15:00 |
Czytaj oryginał (ang.) |